10-Q Filing

INSIGHT MOLECULAR DIAGNOSTICS INC. CIK: 1642380 Q3 2021

Filing Information

Form Type	10-Q
Accession Number	`0001493152-21-027698`
Period End Date	20210930
Filing Date	20211109
Fiscal Year	2021
Fiscal Period	Q3
XBRL Instance	form10-q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 83 Income Statement 88 Cash Flow Statement 115 Stockholders Equity 40

Balance Sheet 83 line items

Line Item	Tag	Value	Unit	Period
Preferred stock no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.14M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$43.34M	USD	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$1.03M	USD	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$203.00K	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$675.00K	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$923.00K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	230.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	230.00M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.21M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$2.30M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$47.59M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	92.16M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	69.12M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$9.23M	USD	Point-in-time
Common stock, shares, outstanding	`CommonStockSharesOutstanding`	92.16M	shares	Point-in-time
Common stock, shares, outstanding	`CommonStockSharesOutstanding`	69.12M	shares	Point-in-time
Right-of-use and financing lease assets, net	`FinanceLeaseRightOfUseAsset`	$3.26M	USD	Point-in-time
Right-of-use and financing lease assets, net	`FinanceLeaseRightOfUseAsset`	$2.92M	USD	Point-in-time
Machinery and equipment, net, and construction in progress	`MachineryAndEquipmentNetAndConstructionInProgress`	$3.26M	USD	Point-in-time
Machinery and equipment, net, and construction in progress	`MachineryAndEquipmentNetAndConstructionInProgress`	$4.72M	USD	Point-in-time
Equity method investment in Razor	`EquityMethodInvestments`	$13.42M	USD	Point-in-time
Equity method investment in Razor	`EquityMethodInvestments`	-	USD	Point-in-time
Goodwill	`Goodwill`	$9.24M	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Goodwill	`Goodwill`	$18.43M	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$15.01M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$92.72M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$1.70M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$1.70M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$356.00K	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$259.00K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$55.42M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$168.34M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.20M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$432.00K	USD	Point-in-time
Accrued compensation	`AccruedLiabilitiesCurrent`	$3.47M	USD	Point-in-time
Accrued compensation	`AccruedLiabilitiesCurrent`	$3.34M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$2.28M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$1.87M	USD	Point-in-time
Accrued severance from acquisition, current	`AccruedSeveranceFromAcquisitionCurrent`	-	USD	Point-in-time
Accrued severance from acquisition, current	`AccruedSeveranceFromAcquisitionCurrent`	$2.45M	USD	Point-in-time
Accrued liabilities from acquisition, current	`BusinessCombinationContingentConsiderationLiabilityCurrent`	$2.24M	USD	Point-in-time
Accrued liabilities from acquisition, current	`BusinessCombinationContingentConsiderationLiabilityCurrent`	-	USD	Point-in-time
Loans payable, current	`LoansPayableCurrent`	$2.39M	USD	Point-in-time
Loans payable, current	`LoansPayableCurrent`	$1.50M	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$422.00K	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$786.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$13.38M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$9.00M	USD	Point-in-time
Loans payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	$1.51M	USD	Point-in-time
Loans payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	$178.00K	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$4.31M	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$3.76M	USD	Point-in-time
Contingent consideration liabilities, noncurrent	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$51.67M	USD	Point-in-time
Contingent consideration liabilities, noncurrent	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$7.12M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$21.94M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$68.99M	USD	Point-in-time
Commitments and contingencies (Note 10)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, no par value, 230,000 shares authorized; 92,158 and 69,117 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	`CommonStockValue`	$251.24M	USD	Point-in-time
Common stock, no par value, 230,000 shares authorized; 92,158 and 69,117 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	`CommonStockValue`	$157.16M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-123.68M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-151.89M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$30.84M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$39.59M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$34.64M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$33.48M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$102.67M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$99.35M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$55.42M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$168.34M	USD	Point-in-time

Income Statement 88 line items

Line Item	Tag	Value	Unit	Period
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$555.00K	USD	1 Quarter
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$713.00K	USD	3 Qtrs
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.14M	USD	3 Qtrs
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$984.00K	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$1.14M	USD	3 Qtrs
Cost of revenues	`CostOfRevenue`	$2.95M	USD	3 Qtrs
Cost of revenues	`CostOfRevenue`	$601.00K	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$860.00K	USD	1 Quarter
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$2.37M	USD	3 Qtrs
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	-	USD	3 Qtrs
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$990.00K	USD	1 Quarter
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	-	USD	1 Quarter
Gross profit	`GrossProfit`	$-866.00K	USD	1 Quarter
Gross profit	`GrossProfit`	$-426.00K	USD	3 Qtrs
Gross profit	`GrossProfit`	$-46.00K	USD	1 Quarter
Gross profit	`GrossProfit`	$-1.18M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$2.62M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$8.00M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$9.04M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$3.14M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$125.00K	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$2.93M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$1.57M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$7.86M	USD	3 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$4.62M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$18.19M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$13.38M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$5.50M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$5.00M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	-	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.17M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$2.26M	USD	3 Qtrs
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-2.98M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-2.98M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$37.35M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$6.20M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$12.74M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$23.02M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-125.00K	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-38.53M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-6.24M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-13.60M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-23.44M	USD	3 Qtrs
Interest expense, net	`InterestIncomeExpenseNet`	$-78.00K	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNet`	$-50.00K	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNet`	$-167.00K	USD	3 Qtrs
Interest expense, net	`InterestIncomeExpenseNet`	$-175.00K	USD	3 Qtrs
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-138.00K	USD	1 Quarter
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$248.00K	USD	3 Qtrs
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-18.00K	USD	3 Qtrs
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$20.00K	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-1.11M	USD	3 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-270.00K	USD	3 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-482.00K	USD	1 Quarter
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	1 Quarter
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	3 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	1 Quarter
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	$1.14M	USD	3 Qtrs
Other income, net	`OtherNonoperatingIncomeExpense`	$31.00K	USD	3 Qtrs
Other income, net	`OtherNonoperatingIncomeExpense`	$10.00K	USD	3 Qtrs
Other income, net	`OtherNonoperatingIncomeExpense`	$1.00K	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$-8.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-1.27M	USD	3 Qtrs
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-196.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-539.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$962.00K	USD	3 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-37.57M	USD	3 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-24.72M	USD	3 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-13.80M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-6.78M	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-9.36M	USD	3 Qtrs
Income tax benefit	`IncomeTaxExpenseBenefit`	$-1.09M	USD	3 Qtrs
NET LOSS	`NetIncomeLoss`	$-125.00K	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-28.21M	USD	3 Qtrs
NET LOSS	`NetIncomeLoss`	$-13.80M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-6.78M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-23.62M	USD	3 Qtrs
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.10	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.36	USD	3 Qtrs
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.32	USD	3 Qtrs
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.15	USD	1 Quarter
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	87.81M	shares	3 Qtrs
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	67.25M	shares	1 Quarter
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	91.45M	shares	1 Quarter
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	64.84M	shares	3 Qtrs

Cash Flow Statement 115 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-125.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-28.21M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-13.80M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.78M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-23.62M	USD	3 Qtrs
Depreciation expense	`Depreciation`	$255.00K	USD	1 Quarter
Depreciation expense	`Depreciation`	$529.00K	USD	3 Qtrs
Depreciation expense	`Depreciation`	$69.00K	USD	1 Quarter
Depreciation expense	`Depreciation`	$582.00K	USD	3 Qtrs
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$2.37M	USD	3 Qtrs
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$59.00K	USD	3 Qtrs
Amortization of right-of-use assets and liabilities	`AmortizationOfRightOfUseAssetsAndLiabilities`	$959.00K	USD	3 Qtrs
Amortization of right-of-use assets and liabilities	`AmortizationOfRightOfUseAssetsAndLiabilities`	$169.00K	USD	3 Qtrs
Impairment charge for long-lived assets	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	$88.00K	USD	3 Qtrs
Impairment charge for long-lived assets	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	-	USD	3 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-1.11M	USD	3 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-270.00K	USD	3 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-482.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$1.85M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$4.08M	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$5.14M	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$1.78M	USD	1 Quarter
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-138.00K	USD	1 Quarter
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$248.00K	USD	3 Qtrs
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-18.00K	USD	3 Qtrs
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$20.00K	USD	1 Quarter
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$80.00K	USD	3 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$46.00K	USD	3 Qtrs
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.17M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$2.26M	USD	3 Qtrs
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-2.98M	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-2.98M	USD	3 Qtrs
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-1.09M	USD	3 Qtrs
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-9.36M	USD	3 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	1 Quarter
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	3 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	1 Quarter
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	$1.14M	USD	3 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$372.00K	USD	3 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$824.00K	USD	3 Qtrs
Amount due to Lineage and affiliates	`IncreaseDecreaseInDueToRelatedParties`	-	USD	3 Qtrs
Amount due to Lineage and affiliates	`IncreaseDecreaseInDueToRelatedParties`	$-6.00K	USD	3 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$529.00K	USD	3 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$787.00K	USD	3 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$1.84M	USD	3 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-1.59M	USD	3 Qtrs
Accrued severance from Chronix Biomedical acquisition	`AccruedSeveranceFromChronixBiomedicalAcquisition`	$2.45M	USD	3 Qtrs
Accrued severance from Chronix Biomedical acquisition	`AccruedSeveranceFromChronixBiomedicalAcquisition`	-	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-28.88M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-19.84M	USD	3 Qtrs
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$607.00K	USD	3 Qtrs
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$6.19M	USD	3 Qtrs
Acquisition of Razor Genomics asset, net of cash acquired	`AcquisitionOfRazorGenomicsAssetNetOfCashAcquired`	-	USD	3 Qtrs
Acquisition of Razor Genomics asset, net of cash acquired	`AcquisitionOfRazorGenomicsAssetNetOfCashAcquired`	$6.65M	USD	3 Qtrs
Acquisition of Chronix Biomedical, net of cash acquired	`AcquisitionOfChronixBiomedicalNetOfCashAcquired`	$4.46M	USD	3 Qtrs
Acquisition of Chronix Biomedical, net of cash acquired	`AcquisitionOfChronixBiomedicalNetOfCashAcquired`	-	USD	3 Qtrs
Equity method investment in Razor	`PaymentsToAcquireEquityMethodInvestments`	-	USD	3 Qtrs
Equity method investment in Razor	`PaymentsToAcquireEquityMethodInvestments`	$4.00M	USD	3 Qtrs
Construction in progress and purchases of furniture and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.06M	USD	3 Qtrs
Construction in progress and purchases of furniture and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.85M	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-11.25M	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-13.56M	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$72.00K	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$2.57M	USD	3 Qtrs
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$65.26M	USD	3 Qtrs
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$18.34M	USD	3 Qtrs
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$58.00K	USD	3 Qtrs
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$2.68M	USD	3 Qtrs
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromIssuanceOfPrivatePlacement`	$12.72M	USD	3 Qtrs
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromIssuanceOfPrivatePlacement`	-	USD	3 Qtrs
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	$390.00K	USD	3 Qtrs
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	-	USD	3 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	3 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$2.63M	USD	3 Qtrs
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	$14.00K	USD	3 Qtrs
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	$239.00K	USD	3 Qtrs
Repayment of loan payable	`RepaymentsOfDebt`	$1.12M	USD	3 Qtrs
Repayment of loan payable	`RepaymentsOfDebt`	$125.00K	USD	3 Qtrs
Repayment of financing lease obligations	`FinanceLeasePrincipalPayments`	$127.00K	USD	3 Qtrs
Repayment of financing lease obligations	`FinanceLeasePrincipalPayments`	$53.00K	USD	3 Qtrs
Proceeds from PPP loan	`ProceedsFromIssuanceOfLongTermDebt`	-	USD	3 Qtrs
Proceeds from PPP loan	`ProceedsFromIssuanceOfLongTermDebt`	$1.14M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$19.31M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$78.63M	USD	3 Qtrs
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-11.78M	USD	3 Qtrs
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$36.20M	USD	3 Qtrs
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$11.99M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$45.04M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.77M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$11.99M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$45.04M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.77M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	$131.00K	USD	3 Qtrs
Cash paid for interest	`InterestPaidNet`	$96.00K	USD	3 Qtrs
Common stock issued for acquisition of Razor Genomics asset	`StockIssued1`	-	USD	3 Qtrs
Common stock issued for acquisition of Razor Genomics asset	`StockIssued1`	$5.76M	USD	3 Qtrs
Deferred tax liability generated from the acquisition of Razor Genomics asset	`DeferredTaxLiabilityGeneratedFromAcquisitionOfRazorGenomicsAsset`	$7.56M	USD	3 Qtrs
Deferred tax liability generated from the acquisition of Razor Genomics asset	`DeferredTaxLiabilityGeneratedFromAcquisitionOfRazorGenomicsAsset`	-	USD	3 Qtrs
Common stock issued for acquisition of Insight Genetics	`CommonStockIssuedForAcquisition`	$5.00M	USD	3 Qtrs
Common stock issued for acquisition of Insight Genetics	`CommonStockIssuedForAcquisition`	-	USD	3 Qtrs
Common stock issued for acquisition of Chronix Biomedical	`CommonStockIssuedForAcquisitionOfChronixBiomedical`	-	USD	3 Qtrs
Common stock issued for acquisition of Chronix Biomedical	`CommonStockIssuedForAcquisitionOfChronixBiomedical`	$3.30M	USD	3 Qtrs
Deferred tax liability generated from the acquisition of Chronix	`DeferredTaxLiabilityGeneratedFromAcquisitionOfChronix`	-	USD	3 Qtrs
Deferred tax liability generated from the acquisition of Chronix	`DeferredTaxLiabilityGeneratedFromAcquisitionOfChronix`	$1.79M	USD	3 Qtrs
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	$42.30M	USD	3 Qtrs
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	$11.13M	USD	3 Qtrs
Assumed liability from Chronix Acquisition	`AssumedLiabilityFromChronixAcquisition`	$3.49M	USD	3 Qtrs
Assumed liability from Chronix Acquisition	`AssumedLiabilityFromChronixAcquisition`	-	USD	3 Qtrs
Holdback liability	`HoldbackLiability`	-	USD	3 Qtrs
Holdback liability	`HoldbackLiability`	$600.00K	USD	3 Qtrs
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability`	$193.00K	USD	3 Qtrs
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability`	$1.11M	USD	3 Qtrs

Stockholders Equity 40 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$30.84M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$39.59M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$34.64M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$33.48M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$102.67M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$99.35M	USD	Point-in-time
Net Loss	`NetIncomeLoss`	$-125.00K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-28.21M	USD	3 Qtrs
Net Loss	`NetIncomeLoss`	$-13.80M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-6.78M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-23.62M	USD	3 Qtrs
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$5.14M	USD	3 Qtrs
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$1.78M	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$1.85M	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$4.08M	USD	3 Qtrs
Sale of common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueNewIssues`	$18.34M	USD	3 Qtrs
Sale of common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueNewIssues`	$77.99M	USD	3 Qtrs
Sale of common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueNewIssues`	$6.24M	USD	1 Quarter
Financing costs paid to issue common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueOther`	$-187.00K	USD	1 Quarter
Financing costs paid to issue common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueOther`	$-27.00K	USD	1 Quarter
Financing costs paid to issue common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueOther`	$-58.00K	USD	3 Qtrs
Financing costs paid to issue common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueOther`	$-3.06M	USD	3 Qtrs
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$72.00K	USD	1 Quarter
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$72.00K	USD	3 Qtrs
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.57M	USD	3 Qtrs
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$974.00K	USD	1 Quarter
Warrants exercised	`StockIssuedDuringPeriodValueWarrantsExercised`	$2.63M	USD	3 Qtrs
Warrants exercised	`StockIssuedDuringPeriodValueWarrantsExercised`	$1.81M	USD	1 Quarter
Shares issued upon vesting of RSU, net of shares retired to pay employees taxes	`SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes`	$-14.00K	USD	3 Qtrs
Shares issued upon vesting of RSU, net of shares retired to pay employees taxes	`SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes`	$-202.00K	USD	1 Quarter
Shares issued upon vesting of RSU, net of shares retired to pay employees taxes	`SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes`	$-239.00K	USD	3 Qtrs
Issuance of common stock to Razor Genomics	`StockIssuedDuringPeriodValueAcquisitionsOne`	$5.76M	USD	3 Qtrs
Issuance of common stock to Chronix Biomedical	`StockIssuedDuringPeriodValueAcquisitionsTwo`	$3.30M	USD	3 Qtrs
Issuance of common stock for Insight Genetics acquisition	`StockIssuedDuringPeriodValueAcquisitions`	$5.00M	USD	3 Qtrs
Ending balance, value	`StockholdersEquity`	$30.84M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$39.59M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$34.64M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$33.48M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$102.67M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$99.35M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.